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re Angiotensin-Converting
nzyme Inhibitors and
eta-Blockers Ineffective in
hildren With Dilated
ardiomyopathy and
eart Failure?
n a retrospective, single-center study of children with dilated
ardiomyopathy, Kantor et al. (1) compared outcomes in children
reated with 3 different heart failure regimens (digoxin alone,
igoxin and angiotensin-converting enzyme inhibitors [ACEI] but
ot beta-blockers [BB], and ACEI-BB combination) in a cohort
f 189 patients. Because the study cohort represents their 30-year
xperience with dilated cardiomyopathy and different treatment
egimens, the allocation to treatment groups was determined by
he era of presentation and guided by the prevailing standards in
dult heart failure therapy. On the basis of their observation that
he transplantation-free survival time was similar among the 3
roups, the authors question whether evolving pharmacologic
reatments for heart failure are as effective in improving survival in
hildren with heart failure as they are in adults. Because ACEI and
B drugs are routinely used in pediatric heart failure, a closer
xamination of their analysis is important.
Unfortunately, there are at least 2 reasons to question the
alidity of their findings. Because the study center became a major
eferral center for heart transplantation halfway through the study,
election bias combined with selection of a composite end point
ikely biases the results toward the null. The more recent patients
those in the ACEI and ACEI-BB groups) are more likely to be
hose referred for heart transplantation and thus likely to have
ore severe heart failure. The similarity in ejection fraction amonghe 3 groups is not by itself compelling enough to eliminate this pelection bias. Second, because the primary end point is a time-
o-event composite outcome for death or transplantation, it
hanges halfway through the study when viewed from a clinical
erspective. It is notable that almost all patients who reached the
rimary end point in the digoxin-only group died, whereas most
atients in the ACEI and ACEI-BB groups reached the primary
nd point by receiving a heart transplant. Because the waiting list
urvival time without a transplant is highly variable and may be
ears in some patients listed for heart failure on oral heart failure
herapy (those listed as Status 2 in the U.S. on the United Network
f Organ Sharing wait list), transplantation could have artificially
hortened the time-to-event outcome for several patients in the
CEI and ACEI-BB groups.
In randomized clinical trials, the comparison groups are similar
n baseline characteristics, and the outcome difference can be
ttributed to the study drug alone. Moreover, the primary end
oint remains the same during the entire study duration. We
ecognize that it has been particularly difficult to conduct random-
zed clinical trials in children with heart failure because of the small
umber of children with heart failure. The largest randomized trial
f a heart failure therapy in children was able to enroll only 161
hildren from 26 centers over a 4-year period of recruitment and
as even then considered potentially underpowered by the authors
o detect outcome differences (2). The difficulty in conducting
arge controlled trials in children with heart failure makes obser-
ational studies important. This study highlights the significant
hallenges faced by investigators with an observational study
esign.
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eply
rs. Singh and Almond engage in some useful conjecture, but
heir argument is not supported by published data, including our
wn (1). Much of their argument revolves around the possible
nterdependence of the choice for angiotensin-converting enzyme
nhibitor (ACEI)/beta-blocker therapy and the selection bias for
ransplantation in “sicker” patients who may have been on these
herapies. They speculate that the bias to perform transplantation
n sicker patients undergoing treatment with ACEI/beta-blocker
herapy artificially and negatively skewed the survival of these
atients with the arrival of the transplant era.
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August 31, 2010:822–4However, the introduction of ACEI therapy in our series (1)
ccurred many years before (1983) the availability of heart trans-
lantation, and in the case of beta-blocker therapy, most patients
1998 to 2004) began to receive this well after transplantation was
stablished. Moreover, we showed that the patients most likely to
ie or receive a transplant were those who did not receive any oral
gents. Regarding the propensity for transplantation, we have
cknowledged this limitation, but have also shown that the advent
f transplantation did not change the probability of the combined
nd point (death or transplantation) being reached when the
re-transplantation and current eras were compared. In addition,
nd contrary to their assertion, we did not show that patients
eceiving digoxin were more likely to die than to receive a
ransplant.
Drs. Singh and Almond’s concern that transplant availability
cts as a bias in treatment strategy is overwrought and also
nsupported by any data. Almost every patient in our practice has
ndergone transplantation from a status of refractory heart failure,
hus representing a de facto failure of medical therapy and
ustifying the concept of a composite end point. This concept is
lso broadly accepted in the pediatric cardiology literature (2,3).
We agree, however, that there has been a tendency to treat
atients with these medications absent a compelling level of
vidence, and we believe also that our experience is helpful inemonstrating equipoise regarding their effectiveness in this set-
ing. Our data emphasize the need for adequately powered
rospective randomized trials of therapy for children with this
roup of diseases.
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